Search results
Showing 101 to 150 of 1515 results for patients and public
In development Reference number: GID-TA11633 Expected publication date: 18 June 2026
Read biographies for all members of NICE's indicator advisory committee.
Finerenone for treating heart failure with preserved or mildly reduced ejection fraction [ID6514]
In development Reference number: GID-TA11651 Expected publication date: 04 June 2026
Inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease [ID6459]
In development Reference number: GID-TA11572 Expected publication date: 21 May 2026
Seladelpar for previously treated primary biliary cholangitis [ID6429]
In development Reference number: GID-TA11540 Expected publication date: TBC
In development Reference number: GID-TA10868 Expected publication date: 15 July 2026
expenditure. You'll find this in the finance and workforce report section in our public board papers. Annual report (PDF) . This...
Involving you in the development of NICE guidance.
Involving you in the development of NICE guidance.
Read biographies for all members of NICE's indicator advisory committee.
This guideline covers rehabilitation strategies for adults who have experienced a critical illness and stayed in critical care. It aims to improve physical, psychological and cognitive outcomes in people who have been discharged from critical care.
Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]
Awaiting development Reference number: GID-TA11215 Expected publication date: 07 May 2026
In development Reference number: GID-TA10143 Expected publication date: TBC
In development Reference number: GID-TA10990 Expected publication date: TBC
Lenacapavir for preventing HIV-1 in people aged 16 years or older [ID6495]
In development Reference number: GID-TA11638 Expected publication date: TBC
In development Reference number: GID-TA11488 Expected publication date: 15 July 2026
In development Reference number: GID-TA11498 Expected publication date: 29 April 2026
How voluntary and community sector organisations can help us develop guidance
How voluntary and community sector (VCS) organisations can help NICE develop guidance
How voluntary and community sector organisations can help us develop guidance
How voluntary and community sector (VCS) organisations can help NICE develop guidance
An outline of the roles and responsibilities of the National Institute for Health and Care Excellence.
In development Reference number: GID-TA11330 Expected publication date: TBC
This document is one of a series describing the processes and methods that NICE uses to carry out technology appraisals. It focuses on the technology appraisal processes
In development Reference number: GID-TA11186 Expected publication date: TBC
In development Reference number: GID-TA11298 Expected publication date: TBC
This guideline covers how to make shared decision making part of everyday care in all healthcare settings. It promotes ways for healthcare professionals and people using services to work together to make decisions about treatment and care. It includes recommendations on training, communicating risks, benefits and consequences, using decision aids, and how to embed shared decision making in organisational culture and practices.
Port Delivery Platform with ranibizumab for treating wet age-related macular degeneration [ID3983]
Awaiting development Reference number: GID-TA10879 Expected publication date: 11 November 2026
This quality standard covers testing, diagnosing and managing hepatitis B in adults, young people and children (from birth). It describes high-quality care in priority areas for improvement.
View quality statements for QS65Show all sections
Sections for QS65
- Quality statements
- Quality statement 1: Testing and vaccination for hepatitis B
- Quality statement 2: Referral for specialist care
- Quality statement 3: Referral to and assessment by specialist care for pregnant women who are identified as hepatitis B surface antigen-positive at antenatal screening
- Quality statement 4: Complete course of neonatal hepatitis B vaccination and blood testing at 12 months
- Quality statement 5: Personalised care plan
- Quality statement 6: Monitoring people with chronic hepatitis B infection who do not meet the criteria for antiviral treatment
- Quality statement 7: 6-monthly surveillance testing for hepatocellular carcinoma in adults with chronic hepatitis B infection who have significant liver fibrosis or cirrhosis
Find out more about the types of organisations that can register to be a stakeholder at NICE.
Find out more about the types of organisations that can register to be a stakeholder at NICE.
This guideline covers managing hip fracture in adults. It aims to improve care from the time people aged 18 and over are admitted to hospital through to when they return to the community. Recommendations emphasise the importance of early surgery and coordinating care through a multidisciplinary Hip Fracture Programme to help people recover faster and regain their mobility.
Palopegteriparatide for treating chronic hypoparathyroidism [ID6380]
In development Reference number: GID-TA11454 Expected publication date: 23 July 2026
In development Reference number: GID-TA11649 Expected publication date: 14 October 2026
This quality standard covers ways to reduce suicide and help people bereaved or affected by suicide. It describes high-quality care in priority areas for improvement.
View quality statements for QS189Show all sections
Sections for QS189
- Quality statements
- Quality statement 1: Multi-agency suicide prevention partnerships
- Quality statement 2: Reducing access to methods of suicide
- Quality statement 3: Media reporting
- Quality statement 4: Involving family, carers or friends
- Quality statement 5: Supporting people bereaved or affected by a suspected suicide
- Update information
- About this quality standard
CaRi-Heart for predicting cardiac risk in adults with suspected coronary artery disease (CAD)
In development Reference number: GID-HTE10085 Expected publication date: TBC
In development Reference number: GID-TA11230 Expected publication date: 07 May 2026
a rapid assessment of flu product zanamivir. First public board meeting Register to attend a public board meeting . 2000...
People and communities - putting you at the heart of our work
NICE is committed to involving people who use services, carers and the public in the development of our guidance and other products.
People and communities - putting you at the heart of our work
NICE is committed to involving people who use services, carers and the public in the development of our guidance and other products.
This guideline covers safe and effective use of medicines in health and social care for people taking 1 or more medicines. It aims to ensure that medicines provide the greatest possible benefit to people by encouraging medicines reconciliation, medication review, and the use of patient decision aids.
In development Reference number: GID-TA11140 Expected publication date: TBC
In development Reference number: GID-TA11232 Expected publication date: 08 April 2026
Read the biographies of our medical technologies advisory committee members.
Find out more about NICE technology appraisals advisory committee D members
In development Reference number: GID-TA10979 Expected publication date: 11 March 2026
Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092]
In development Reference number: GID-TA10994 Expected publication date: TBC
Software for electroencephalogram (EEG) interpretation to support diagnosing epilepsy
In development Reference number: GID-HTE10086 Expected publication date: 15 September 2026
Tell us what matters to you, your organisation or your community.
Tell us what matters to you, your organisation or your community.
Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps ID6379
In development Reference number: GID-TA11429 Expected publication date: 09 September 2026
Find out more about NICE technology appraisals advisory committee D members